Tempus AI Inc. - Ordinary Shares - Class A
TEM
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
177.7% downsideOvervalued by 177.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.81 Billion |
|---|---|
| Enterprise Value | $9.17 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.41 |
| Beta | 3.99 |
| Outstanding Shares | 178,880,000 |
Return
| Return on Equity | -72.74% |
|---|---|
| Return on Assets | -14.19% |
| Return on Invested Capital | -10.32% |
Valuation & Multiples
| P/E Ratio | -29.8 |
|---|---|
| PEG | -35.03 |
| Price to Sales | 6.79 |
| Price to Book Ratio | 23.76 |
| Enterprise Value to Revenue | 6.73 |
| Enterprise Value to EBIT | -48.9 |
| Enterprise Value to Net Income | -31 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 2.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7580▲ 12.50% |
|---|---|
| Total Calls | 11,901,000▼ 22.40% |
| Total Puts | 9,021,204▼ 7.07% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 60.40%▲ 2.71% |
|---|---|
| Total Invested | $4.75B▼ 20.39% |
| Investors Holding | 468▼ 46.00% |
ESG Score
No data
About Tempus AI Inc.
Relevant Senate Committees
As a key advisory body for tax legislation, this committee directly influences corporate tax structures, capital investment credits, and the overall tax burden on companies like Tempus AI, impacting their financial planning and investment decisions.
This powerful committee controls taxation, trade, and entitlement spending (Medicare). Its decisions on corporate tax policy directly impact Tempus AI's profitability, and its influence on healthcare funding and pricing affects the broader market for healthcare technology.
This committee allocates discretionary federal spending. Its subcommittees determine funding for scientific research (e.g., NIH) and federal programs, directly impacting the ecosystem Tempus AI operates within and potential government contracts for its services.
This committee directly regulates the FDA and NIH. Tempus AI's AI-driven diagnostics and precision medicine tools are subject to FDA oversight, and its work benefits from NIH-funded research, making this committee a primary regulatory and funding influence.
This committee oversees antitrust laws and intellectual property. As a growing tech/biotech company, Tempus AI's intellectual property is critical, and potential M&A activities or market dominance could fall under antitrust scrutiny.
Tempus AI provides AI-driven precision medicine solutions. The Department of Veterans Affairs (VA) is a major healthcare provider, and funding decisions by this committee directly impact government healthcare contractors and technology providers that could partner with or sell to the VA.
This committee has vast jurisdiction over interstate commerce, data privacy, and technology regulation (FTC). As an AI company dealing with sensitive patient data, Tempus AI is directly impacted by privacy laws, AI ethics guidelines, and general tech sector oversight.